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ABSTRACT  
We present a novel but simple enteric coated sphere formulation containing probiotic 
bacteria (Lactobacillus casei). Oral delivery of live bacterial cells (LBC) requires live cells to 
survive firstly manufacturing processes and secondly GI microbicidal defenses including 
gastric acid. We incorporated live L. casei directly in the granulation liquid, followed by 
granulation, extrusion, spheronization, drying and spray coating to produce dried live 
probiotic spheres. A blend of MCC, calcium-crosslinked alginate, and lactose was developed 
that gave improved live cell survival during manufacturing, and gave excellent protection 
from gastric acid plus rapid release in intestinal conditions. No significant loss of viability was 
observed in all steps except drying, which resulted in approximately 1 log loss of viable cells. 
Eudragit coating was used to protect dried live cells from acid, and microcrystalline cellulose 
(MCC) was combined with sodium alginate to achieve efficient sphere disintegration leading 
to rapid and complete bacterial cell release in intestinal conditions. Viability and release of L. 
casei was evaluated in vitro in simulated GI conditions. Uncoated spheres gave partial acid 
protection, but enteric coated spheres effectively protected dried probiotic LBC from acid for 
2 h, and subsequently released all viable cells within 1h of transfer into simulated intestinal 
fluid. 
 
KEYWORDS  
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ABBREVIATIONS 
DLPS, dried live probiotic spheres; LBC, live bacterial cells; SIF, simulated intestinal 
fluid (pH 7.0); SGF, simulated gastric fluid (pH 1.8); CFU, colony forming unit; GI, 
gastrointestinal. 
Introduction 
Live bacterial cells (LBC) can be administered as pharmaceuticals, nutraceuticals or 
food supplements, with potential to treat and prevent disease or improve health (Cook et al., 
2012). Probiotics are defined by the World Health Organization (WHO) and the Food and 
Agriculture Organization (FAO) as “live microorganisms which when administered in 
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adequate amounts confer health benefit on the host” with many proposed benefits (Bron et 
al., 2012; Fuller, 1991).  
Although a probiotic dose of 107 microorganisms/ g or mL is recommended to 
promote a beneficial host response, the required number of bacteria varies depending on the 
strain and application (Corcoran et al., 2008). Usually, after fermentation and harvest, a 
probiotic formulation starts with a cell density of 109 colony forming units (CFU) / mL or g or 
higher. However, this number typically suffers significant losses during manufacturing 
processes, where the most detrimental step is drying, due to osmotic and oxidative shock 
(Fu and Chen, 2011), but dehydration is necessary for long term preservation of live bacteria 
in solid oral doses (Morgan et al., 2006). Furthermore, after oral administration bacterial cells 
must survive the natural antimicrobial human defences, such as gastric juice, bile and 
enzymes (de Barros et al., 2014; Edwards and Slater, 2008, 2009; Solanki et al., 2013).  
Effective oral delivery of therapeutic live bacterial cells is therefore challenging. 
Firstly the bacterial cells has to be delivered alive, metabolically active and in high numbers. 
Secondly, the formulation should offer targeting and controlled release to the site of action, 
which for LBC is usually the distal small intestine (typical for live bacterial vaccines) or the 
colon (typical target for probiotics). An increase in viability can be achieved by entrapment of 
the bacterial cells in a polymeric matrix that offers both acid and possibly bile protection, and 
is non-toxic to either the bacterial cells or the host using microencapsulation processes such 
as coacervation, tableting or pelletization (Cook et al., 2012). Alternatively targeting can be 
achieved using a polymeric coating, such as an enteric coating, to exclude gastric acid but 
subsequently dissolve as pH rises in the intestine. 
Formulations that target the intestine require several features. They should be easy 
to swallow, allow large drug doses which could be divided into small units, give the potential 
of combining various active ingredients in the same unit, offer good flow properties improving 
capsule filling and offer a fast gastric emptying time, decreasing the residence time in the 
presence of detrimental gastric fluids. Enteric coated spheres fulfil these requirements. 
Furthermore, spheres with smooth surface morphology, high density and low friability can be 
individually coated, ensuring each pellet behaves as a single unit, and thus coating defects 
only affect a small proportion of the therapeutic dose (Abdul et al., 2010; Dukić-Ott et al., 
2009). 
The most common manufacturing processes to produce uniform spheres for oral 
administration is extrusion-spheronization as it is highly efficient and allows continuous batch 
process permitting a highly scalable output (Vervaet et al., 1995). A powder mixture of the 
therapeutic agents and excipients is wetted by adding the granulation liquid (wet granulation) 
with mixing until it becomes a uniform plastic mass. The wet mass is extruded through a 
screen or die with different lengths and diameters, forming tubular extrudates. These are 
then transferred to a spheronizer where they are broken down, first into small rods and after 
into spheroid particles as a consequence of the collision imposed by a fast spinning friction 
disk. Finally they are dried in either a tray or fluidized bed drier (Vervaet et al., 1995).  
Drug release from spheres is composition dependent. Microcrystalline cellulose 
(MCC) is the excipient of choice for extrusion-spheronization as it provides ideal rheological 
properties, can be an excellent binder, promotes cohesiveness, and has the ability to absorb 
and hold large amounts of water as a result of a great porosity and large surface area 
(Dukić-Ott et al., 2009; Sonaglio et al., 1995). Drug release from MCC pellets is typically 
controlled via diffusion through the polymer matrix. However, in some cases MCC is not an 
appropriate excipient, for example due to chemical incompatibility, drug adsorption by MCC, 
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variation of performance from different suppliers, and minimal or prolonged drug release due 
to delayed disintegration of MCC-based pellets (Dukić-Ott et al., 2009). Lack of 
disintegration may not be a major problem for many small APIs able to diffuse through the 
matrix, but for low-solubility drugs, large agents, and for intestinal delivery where solid 
formulations require enteric coating followed by rapid release on arrival to the target site, 
pellet disintegration is necessary. Several approaches have achieved rapid pellet 
disintegration and a “burst release” effect, including inclusion of disintegrants, surface active 
agents, co-solvents and fillers. Schroder at al showed that MCC pellet disintegration can be 
improved by using a solvent mixture, usually alcohol/water, as liquid binder in place of water 
(SchrÖDer and Kleinebudde, 1995). To ensure disintegration in LBC formulations, the 
amount of MCC should thus be kept low and combined with other excipients that are suitable 
for sphere formation, compatible with enteric delivery, have disintegrant properties, and are 
compatible with live bacterial cells.  
Prior work demonstrated that it is feasible to produce spheres containing live bacteria 
by extrusion-spheronization (Bajaj et al., 2010; Brachkova et al., 2009; Huyghebaert et al., 
2005a; Kim et al., 1988; Kouimtzi et al., 1997). However, none of these studies combined all 
necessary elements for effective LBC delivery, namely: survival during processing; 
protection from gastric acid; and full disintegration to release cells after transfer into intestinal 
conditions. Several reports showed that LBC sphere production using extrusion-
spheronisation is feasible, but lacked study of gastric acid resistance, and no 
gastroprotective coating was used (Bajaj et al., 2010; Huyghebaert et al., 2005a; Kouimtzi et 
al., 1997). A recent study examined cell survival during production and eudragit spray-
coating of MCC pellets and mini-tablets, and also studied storage stability and water content; 
however this did not report if these coated formulations had appropriate acid protection and 
cell release profiles in simulated gastrointestinal conditions (Brachkova et al., 2009). 
In this study we examined whether a more sophisticated excipient blend could 
provide the required combination of acid resistance followed by complete release of LBC, 
whilst maintaining cell viability during manufacture. We combined MCC with sodium alginate, 
lactose and CaCl2 to formulate Lactobacillus casei as a model probiotic. We adapted a 
similar MCC/alginate/lactose sphere formulation that was previously developed for oral 
delivery and controlled release of small molecule drugs into the stomach (Sriamornsak et al., 
2007). Although alginate can itself provide gastroprotection, acid still penetrates into 
alginate-chitosan microcapsules leading to loss of viability (Cook et al., 2013) and so we 
investigated if an enteric coating was also required to fully protect dried bacteria from gastric 
acid. A methacrylic acid copolymer type C (Eudragit L100-55), in a fully formulated coating 
dispersion (Acryl EZE) was spray coated onto spheres in a fluidized bed. 
In many previous formulations bacteria were either freeze-dried (Brachkova et al., 
2009) or thermal dried (Bajaj et al., 2010) and added to the formulation in powder form, 
leading to rehydration of cells followed by a second drying step. Here, for the first time we 
incorporated the therapeutic live bacteria directly into the granulation fluid, combined with the 
CaCl2 solution used to crosslink alginate. 
Using this novel approach we aimed to produce an enteric coated dried live probiotic 
sphere (DLPS) formulation suitable for delivery of viable probiotic L. casei. The composition 
and processing parameters were optimized to produce uniform spheres with maximum 
viability. The spheres produced were fully characterized, determining morphological 
properties, disintegration profile, and survival and release of lactobacilli was monitored from 
uncoated and coated DLPS during simulated transit through the GI tract. We used 
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Lactobacillus casei, a model lactic acid producing bacterium that has been used in 
commercial products for over two decades, and has a high resistance to pharmaceutical 
technological processes, good in vitro human cells adherence properties and has 
antimicrobial effects against several Gram negative and Gram positive pathogens (Forestier 
et al., 2001).  
Materials 
Microcrystalline cellulose (Avicel PH-101) (MCC) was a kind gift from FMC 
Biopolymer (UK), Acryl-EZE was given by Colorcon (Dartford Kent, UK), sodium alginate (19 
– 40 KDa) and calcium chloride were purchased from Sigma-Aldrich (Gillingham, UK). 
Lactose monohydrate (100 mesh) was purchased from DMV International (Netherlands). 
Lactobacilli Man, Rogosa and Sharpe (MRS) broth and agar, and phosphate-buffered saline 
(PBS) were purchased from Oxoid (Basingstoke, UK). The probiotic strain Lactobacillus 
casei NCIMB 30185 (PXN 37) was provided by Probiotics International Ltd (Protexin) 
(Somerset, UK). 
Methods 
Preparation of live bacterial cell suspensions 
Single colonies of L. casei from MRS agar were inoculated into 10 mL MRS broth 
and incubated at 37 °C for 24 hours to obtain cultures with an OD600 of 1.9 - 2.0, 
corresponding to early stationary growth phase. The 10 mL aliquots of cells were harvested 
in centrifuge tubes by centrifugation (3200 rpm, 10 min, 4 °C), the supernatants removed 
and the cell pellets were washed in 1 mL PBS and resuspended in 13 mL sterile 3 % (w/v) 
calcium chloride in deionized water to give approximately 109 cfu/mL. This solution was 
freshly prepared and used as granulation liquid. 
Production of uncoated DLPS formulation by extrusion-spheronisation 
A wet powder mass was prepared by mixing the powder excipients, comprising a 
5:3:2 mass ratio in grams of dry reagents MCC, sodium alginate, and lactose, plus 13 mL 
granulation fluid per 10 g of dry ingredient (comprising L. casei suspension with 3% w/v 
CaCl2 as the granulation fluid) using an overhead stirrer. A total dry ingredient batch of 10 g 
dry ingredients – i.e. 5 g MCC, 3 g sodium alginate, and 2 g lactose – were pre-blended for 5 
min at 50 rpm using an overhead mixer (IKA RW 20.n) with a square shape mixing arm, and 
subsequently wetted by gradual addition of 13 mL of granulation liquid, and granulated for 
15 min at ambient temperature. This time was established as necessary to produce a 
homogeneous and cohesive plastic mass. 
The mix was then extruded using a Mini Screw Extruder (Caleva Instruments, model 
extruder 20, UK) at a constant perforated speed of 50 rpm, using a die of 4-mm length and 
1-mm diameter, giving an L/R ratio of 4. The angle of extrusion was 90 ° and the barrel 
orientation enables the extrudate to be sampled during the process. All extrudates were 
spheronized at 1875 rpm for 5 min using a laboratory scale spheronizer (Caleva Instruments 
MBS 120 - Multi Bowl Spheronizer, UK), having a cross-hatch plate with a diameter of 12 
cm. Wet spheres were dried in a Mini Coater Drier - 2 (Caleva Instruments, UK) at 40 ºC 
inlet air temperature for 35 minutes. Spheres in the size range of 1.0 – 1.4 mm were 
collected for further experiments. Samples were taken at the end of each step to assess cell 
viability during the manufacturing process.  
Enteric coating of spheres 
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Acryl-Eze® MP is a fully formulated dry enteric coating system dispersible in water. 
The suspension was prepared using 20 % (w/w) of powder dispersed in water. A mechanical 
stirrer was used to generate a homogeneous suspension. Based on the manufacturer's 
instructions, the suspension was agitated for 60 min and filtered through a 400 μm sieve. 
Throughout the coating process the coating dispersions were continuously mixed using a 
magnetic stirrer. Spheres were coated in a Mini Coater Drier - 2 (Caleva Instruments, UK) 
using the top spray mode (nozzle diameter 0.8 mm; atomising pressure 10 psi). The spray 
rate was 11 mL/h for the Eudragit. For all coating experiments, the product temperature was 
35 ºC. Before coating, the DLPS were pre-heated to the desired product temperature during 
coating. During coating, the pellets were weighed until a mass gain of 20 % was obtained. 
After coating, the pellets were left to cure in the apparatus for 15 min at the same conditions 
as the coating process to achieve complete coalescence of the polymer particles. The 
pellets were packed in plastic containers, sealed and stored at room temperature for 
characterization, or on ice for viability experiments. 
 
Water content 
The residual water content of the uncoated and coated dosage forms was 
determined by thermogravimetric analysis (TGA), with 5 °C/min ramp rate from 25 °C to 200 
°C in a TA instruments Q500 Thermogravimetric Analyzer (TA instruments, Crawley,UK). 
 
Evaluation of the DLPS – physical characterization 
Size, shape and sphericity  
The size distribution influences release kinetics (Husson et al., 1992), and was 
screened by using a nest of sieves with aperture diameters ranging from 0.075 mm to 1.4 
mm by means of a sieve particle sizer (Germany) operating at the vibrational modus of 1 – 3 
mm for 5 min. The uncoated spheres selected for this study belonged to the fraction size 
from 1.0 – 1.4 mm, these were collected and used for further analysis. Visual inspection of 
the uncoated and coated spheres was conducted using a light microscope (Leica DM2500) 
combined with a camera and image analysis software (ImageJ). The shape factor of the 
spheres is an important characteristic and generally the aspect ratio and the circularity 
values are used to classify their shape independent of the size, by microscopy and image 
analysis. For each formulation 25 spheres were randomly selected for measurement and the 
results presented as average ± standard deviation. 
 
Crushing strength - Mechanical tests 
The crushing strength (the load needed to break the particles) of 25 spheres (coated 
or uncoated) were determined by texture analysis (Texture Analyser, Stable Microsystems, 
UK). Texture analysis was performed with a P\6 steel probe at a rate of 0.03 mm/s, using a 
trigger force of 0.98 N. The crushing strength was taken at the point at which the sphere was 
seen to fracture on the graph of compressive force against distance. 
Fourier transformed infrared (FT-IR) spectroscopy 
Both non-coated and coated spheres were grounded into a fine powder using a 
pestle and mortar before analysis. Previous mixtures and individual powders of sodium 
alginate, lactose monohydrate, MCC, and Acryl-EZE were scanned at a resolution of 4 cm-1 
over a wavenumber region of 500 – 4000 cm-1 using a Perkin Elmer 100 spectrum FT-IR 
spectrophotometer. 
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Surface morphology - Scanning electron microscopy (SEM) 
The morphology of the surface and a cross section of the coated and uncoated 
spheres were characterized using SEM (scanning electron microscopy). The spheres were 
mounted on an aluminium stub, sputter-coated with a thin layer of gold using sputter coater 
(Polaron, UK) under argon atmosphere, and then examined using SEM (LEO1450VP, UK). 
Swelling, disintegration and floatability during simulated gastrointestinal 
transit 
Simulated gastric fluid (SGF) was prepared containing 0.2% (w/v) NaCl, and adjusted 
to pH 1.8 with 1 M HCl chosen as the average adult gastric pH in the fasted state. Simulated 
intestinal fluid (SIF) was prepared by dissolving 0.68 % (w/v) monobasic potassium 
phosphate (KH2PO4) in deionized water and adjusting to pH 7.0 with 1 M NaOH. Individual 
uncoated or coated spheres were placed into a vial containing SGF (3 mL) or SIF (6 mL) and 
kept at 20 °C without shaking, and with all spheres completely submerged. For SGF, the 
swelling of the spheres was measured by images taken every 30 min for 120 min; the 
spheres in SIF were measured every 10 min until disintegration. The swelling degree was 
then calculated using an image analysis software (ImageJ), normalizing to the initial 
diameter using equation 1. 
 
                     Swelling degree                                          (1) 
 
Where Dt is the diameter of the spheres at time t, and D0 is the diameter at time 0. Each 
experiment was repeated 4 times, and the mean ± standard deviation calculated.  
The sphere disintegration in gastrointestinal solutions was evaluated by image 
recording. For the disintegration experiment MCC core spheres were prepared with 
microcrystalline cellulose as powder and water as granulation liquid, and formulated by the 
extrusion-spheronization method. For this experiment MCC spheres, coated and uncoated 
DLPS spheres (1 g) were placed into SGF (2 h, 50 mL, 37 °C, with shaking at 100 rpm) and 
SIF (24 h, 100 mL, 37 °C, with shaking at 100 rpm). The disintegration was observed by 
recording images every 30 min during 2 h in SGF, followed by transferring the spheres into 
SIF for 24 h. In this experiment, images were taken every 30 min for 4 hours and then after 
24h. 
Floatability was performed by adding 1 g of spheres to SGF (50 mL, 37 °C, stirring 
rate of 100 rpm) for 2 hours and the floating sphere (%) of non-coated and coated spheres 
was determined by counting. Floatability is an important parameter as it helps to determine 
sphere behaviour, swelling, disintegration and flow in gastrointestinal solutions. 
 
      Floating sphere (%) =                                                                          (2) 
 
Survival of free and encapsulated L. casei in SGF 
For free cells, L. casei was inoculated in 10 mL MRS broth, and incubated at 37 °C 
for 24 h. After incubation and cell growth, a 1 mL sample was taken to determine initial cell 
numbers by the serial dilution and plate count method. Briefly, cells were serially diluted in 
vials containing PBS, and 0.1 mL spread onto MRS agar. Plates were incubated aerobically 
(37 °C, 48 h) and then the number of colony forming units (CFU) was counted. For survival 
in acid conditions, 10 mL aliquots of cell suspension were harvested in centrifuge tubes by 
centrifugation (3200 rpm, 10 min, 4 °C), supernatants removed and cell pellets were washed 
in 1 mL PBS followed by resuspension in either PBS (10 mL, starting cell viability) or 
D
0 
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simulated gastric fluid (SGF, 10 mL, time 0 in acid) before enumeration as described above. 
The cells in SGF were placed in an incubator for 2 h (37 °C, with orbital shaking at 100 rpm), 
after, an aliquot (1 mL) was removed for enumeration. Viable counts were determined by 
serial dilution in PBS followed by plating on MRS agar plates as previously described. 
For uncoated and coated DLPS, samples of 3 batches of each formulation (1 g) were 
either disintegrated in PBS (9 mL) for calculating the starting numbers after processing, or 
suspended in SGF (50 mL) and placed in an incubator for 2 h (37 °C, with orbital shaking at 
100 rpm). After 2 hours the solution was placed into a stomacher (Seward Stomacher 400 
circulator) for 20 minutes. Viable counts of the bacterial cells suspension were determined 
by serial dilution in PBS, followed by plating on MRS agar plates. Each experiment was 
repeated 4 times, and the mean ± standard deviation calculated. 
Evaluation of the DLPS during manufacturing – cell viability 
Live cell recovery was evaluated using serial dilution of samples and agar plate 
colony counting after each step: slurry, mixing, extrusion, spheronization, drying and enteric 
coating, and during acid resistance and dissolution tests. Serial dilutions were made in PBS 
with a pipettor. In detail, samples of powder (1 g), wet mass, extrudate, or spheres were 
weighed into 9 mL of PBS and allowed to dissolve, of which 1 mL samples were transferred 
into 9 mL of PBS; 7 serial 10-fold dilutions and 100 µL samples of each dilution were then 
spread onto petri dishes of MRS agar to give dilution factors of 103 to 109. To determine the 
lowest detection limit of 103 CFU/mL, 10 µL samples were also plated directly from the 
rehydration medium. L. casei plates were incubated aerobically at 37 °C for at least 48 h. 
Colonies were counted and final viability expressed as colony forming unit per mL or g 
(CFU/mL or CFU/g) calculated relative to the initial wet mass. To follow viable cell recovery 
after drying and exposure to simulated GI conditions, viable cell counts were expressed 
relative to the initial wet mass before drying. Each experiment was repeated 3 times, and the 
mean ± standard deviation calculated. 
 
Protection and live cell release from DLPS formulation in simulated 
gastrointestinal conditions 
Uncoated and coated DLPS formulations were immersed in simulated gastric fluid 
(SGF) (pH 1.8, 50 mL) and incubated (37 °C, 2 h with orbital shaking at 100 rpm). Samples 
were taken at 1 and 2 h and live cell release determined, although DLPS formulations 
appeared to remain intact in SGF with no dissolution or cell release detected by visual 
inspection. After 2 h in SGF, formulations were removed by filtration and transferred into 100 
mL simulated intestinal fluid (SIF) and incubated (37 °C, 3 h with orbital shaking at 100 rpm). 
Samples were taken and live cell release determined at 1, 2 and 3 h after transfer from SGF 
by serial dilutions and viable count plating as described above. For each experiment the 
starting live cell dose corresponded to the post-drying viable cell number prior to in vitro 
testing of DLPS formulations. Each experiment was repeated 3 times, and the mean ± 
standard deviation calculated. 
Statistical analysis   
Data and results are reported as mean with error bars indicating standard deviation. 
Statistical evaluation of comparing the significance of the difference in viability between the 
means of two groups was performed using a two-tailed unpaired Student’s t-test; a value of 
p < 0.05 was accepted as significant. 
8 
 
 
Results 
Appearance, size, shape, crushing strength and surface morphology 
Prior to formulating live cells, we optimized a method to develop and produce small 
spherical particles by extrusion-spheronization. Drug loaded spherical particles offer great 
advantages, but to be effective, the final particles have to present good morphological 
properties. The critical characteristics of formulated coated and uncoated spheres were 
determined, namely appearance, size, shape, crushing strength and surface morphology 
(Table 1). Images of individual spheres clearly show spherical particles; this was also 
demonstrated by the shape measurements of the spheres. Sphericity and aspect ratio gave 
values between 0.9 and 1.0, indicating great spherical geometry (aspect ratio and circularity 
of 1.0 is ideal, as this value corresponds to the circle geometry). As expected, coating of the 
spheres improved their shape and surface morphology. SEM images of both formulations 
also confirms a spherical geometry, and indicated a difference in sphere surface 
morphology, with coated spheres presenting a smoother surface than uncoated spheres 
(Figure 2). Differences in surface morphology are apparent when the sphere surface was 
examined more closely by SEM (Figure 2b vs 2f). Furthermore, cross-section SEM 
photographs showed that both uncoated and coated spheres had porous cores. Also, it can 
be seen that the uncoated spheres had a discontinuous and porous surface. In contrast 
coated spheres presented an even coating layer of approximately 20 µm (Figure 2). 
Moreover, the application of an external layer also increased the force necessary to break 
the coated spheres into small particles by 45 % when compared to uncoated spheres 
showing that these spheres become stronger and denser.  
The presence of the enteric polymer as a coating layer was evaluated by FT-IR 
spectroscopy (Figure 3). The characteristics bands of the C  O vibrations of the carboxylic 
acid groups at 1705 cm-1 and of the esterified carboxylic groups at 1734 cm-1 are typical of 
the methacrylic acid:ethyl acrylate copolymer Eudragit L100 55, which is the main 
component of the fully formulated coating suspension Acryl EZE used in this study. These 
two bands were not detected with uncoated spheres, but were clearly detected with coated 
spheres, confirming the presence of Eudragit in this formulation. 
Swelling and disintegration of DLPS in simulated gastrointestinal fluids 
Formulated spheres were imaged in gastrointestinal solutions to evaluate the effect 
of sphere composition on the disintegration time, and thereby optimise formulation to 
achieve the requisite disintegration to fully release live bacterial cells. Spheres prepared 
using only MCC did not disintegrate in gastrointestinal conditions even after 24 h in SIF, 
following 2 h in gastric fluid (Figure 4). However, reducing the amount of MCC by half 
accompanied by the addition of sodium alginate and lactose resulted in sphere disintegration 
after 1 h in intestinal fluid (Figure 4). Furthermore, both uncoated and coated DLPS did not 
disintegrate during 2 h in SGF, but after 1 h in SIF sphere disintegration was observed, 
showing that the extra coating layer did not prevent sphere disintegration (Figure 4). 
Although coated spheres did disintegrate effectively, the enteric polymer coating did delay 
the onset of disintegration from around 20 minutes to around 60 minutes (Figure 5), 
reflecting the time required for dissolution of the enteric polymer prior to onset of 
disintegration. However, in spite of this delay, full disintegration was achieved which is 
necessary for complete release of bacterial cells. 
During 2 h in SGF at pH 1.8 the degree of swelling of both uncoated and coated 
spheres was low, and neither type of sphere floated in SGF (Figure 5a). The swelling degree 
of uncoated spheres reached a plateau of 0.1 after 40 minutes, but in contrast, coated 
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spheres showed continuous swelling in SGF during 2 h reaching a maximum of 0.27, almost 
three times higher than the uncoated spheres. When placed directly into SIF at pH 7.0, a 
rapid and continuous swelling was observed until disintegration of both coated and uncoated 
spheres. However, uncoated spheres swelled faster and to a greater extent than coated 
ones, reaching a value of 0.9 after 40 minutes, nine times higher than in SGF. The coated 
spheres in SIF reach a maximum of 0.7 after 80 minutes, demonstrating that the coating 
delayed disintegration (Figure 5b).  
Interestingly, when spheres were placed in SIF after being exposed to SGF for 2 h in 
order to simulate gastrointestinal passage, both uncoated and coated spheres swell less and 
disintegrated faster, taking 20 and 60 minutes respectively (Figure 5c). These results show 
that the coating layer resulted in the same delay in disintegration time, 40 minutes, 
independent of whether the spheres were placed directly in SIF or placed into SIF after 
being 2 h in SGF. Again, the swelling was faster for the uncoated samples, but these 
spheres swell substantially less (0.2) compared to the ones placed directly into SIF, before 
they started to disintegrate. In contrast, the coated spheres’ swelling was slow during 40 
minutes, followed by a rapid increase in rate of swelling and then disintegration. As 
expected, at high pH, fast swelling was observed for both formulations leading to mechanical 
damage, followed by fragmentation, which led to inaccuracy in our measurement of swelling.  
Viability of L. casei cells during sphere production 
Having established the optimal material composition and process parameters to 
produce enteric resistant spheres that disintegrate appropriately, we evaluated cell survival 
during each step of sphere manufacturing. We started by producing a granulation liquid 
containing LBC by mixing the overnight grown cells with 3 % CaCl2 to give an initial cell 
number of 109 CFU/mL as this CaCl2 concentration has produced good quality spheres 
when sodium alginate was included in the formulation (Sriamornsak et al., 2008). As the 
presence of inorganic ions in solution can sometimes affect cell viability we tested L. casei 
survival after 1 h of exposure to various CaCl2 concentrations (1 – 5 %), but no loss in 
viability was detected (data not shown). The granulation liquid was mixed with powder 
excipients to form a plastic wet mass, followed by extrusion, spheronization, drying and 
coating. Changes in cell viability throughout the process of sphere production were 
expressed relative to wet mass input as residual water content varies during the process 
(Figure 6). From start to finish the total cell loss was no more than 1 log. While cell numbers 
decreased slightly during wet granulation and extrusion, no loss was detected during 
spheronization. The drying process was optimized to decrease the sphere moisture content 
to below 5 % to ensure anhydrobiosis and long term cell survival during storage. This drying 
step itself was responsible for the greatest reduction in cell numbers, with a significant loss 
of ~0.5 log observed. Interestingly, sphere coating with an aqueous enteric polymer 
(Eudragit) solution followed by air curing did not affect cell viability. Using this extrusion-
spheronisation coating method, it was possible to produce DLPS with a final dose of 108 
CFU/g. 
Viability of L. casei in simulated gastric fluid 
Initial tests were conducted to investigate whether the model probiotic L. casei was 
acid resistant, and to assess the efficacy of DLPS formulations in protecting dried cells from 
gastric pH (Figure 7). When free L. casei cells were incubated in SGF (pH 1.8) a decrease in 
viability of 5 log was observed after 2h, confirming the need for enteric encapsulation. The 
uncoated DLPS matrices alone enhanced the survival of the encapsulated cells by 2 log. 
However, after 2h in SGF a significant reduction in bacterial cell numbers was still observed 
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(Figure 7). Gastric acid protection was further improved by adding a thin layer (~20 µm) of 
enteric polymer, producing coated DLPS, which completely protected L. casei cells from acid 
over a period of 2 h, leading to no detectable loss of viability (Figure 7). 
Cell release in in vitro gastrointestinal conditions 
To evaluate the suitability of DLPS produced using standard pharmaceutical methods 
in protecting live dried LBC from gastric acid, and subsequently releasing viable cells into the 
intestine, spheres were tested in simulated gastrointestinal conditions (2 h in SGF pH 1.8 
and 3 h in SIF pH 7.0, 37 °C, shaking at 100 rpm) and cell viability determined at regular 
time points. Coated and uncoated DLPS containing a cell density equivalent to 108 CFU/g 
were produced by extrusion-spheronization.  Coated DLPS retained the bacteria in gastric 
conditions, followed by rapid sphere disintegration upon transfer to intestinal pH giving a 
burst release of viable L. casei cells after 1h, followed by a moderate slow rise over the 
following 3 hours (Figure 8). A complete recovery of live cell compared to the starting cell 
numbers of 108 CFU/g was observed, indicating no loss in cell viability during 2 hours in 
SGF at pH 1.8. Uncoated DLPS released some cells in gastric fluid after 1 h, with no change 
up to 2 h, but again, a burst release of the majority of viable cells was observed in 1 h 
following transfer into intestinal pH. However, uncoated DLPS failed to totally protect the 
cells, resulting in a loss in cell viability during gastrointestinal transit of almost 2 logs overall 
when compared to both the initial starting dose and to the high release of viable cells from 
the coated DLPS. 
Discussion 
The biggest challenges for formulating LBC for solid oral delivery are maintaining 
viability during processing, protecting fragile cells from gastrointestinal conditions such as 
acid, and ensuring controlled release at the appropriate intestinal site. By optimising process 
conditions, enteric coated spheres were successfully produced that overcame these three 
problems. 
 
Maintaining viability during processing 
As expected, the extrusion-spheronization process parameters and matrix 
composition had a significant influence on size, shape and morphology of the spheres 
(Newton et al., 1995; Sinha et al., 2005; Sousa et al., 2002; Vervaet et al., 1995), all of which 
influence the suitability of any probiotic delivery system. These parameters also affected 
bacterial cell viability. The formulation and manufacturing process were therefore optimised 
to produce MCC-Alginate-Lactose spheres with both the required physical properties but 
also to maximize viability of L. casei cells. The latter was achieved by reducing the impact of 
process stresses including mechanical (pressure, shear), temperature variations, or osmotic 
stress (e.g. during drying), each of which can affect viable cell number.  
During wet granulation and extrusion surprisingly little loss in cell viability was seen, 
which was achieved by using mild process conditions and minimising mechanical stresses 
when conditions were optimised (Figure 6). In contrast to previous studies (Huyghebaert et 
al., 2005a; Kouimtzi et al., 1997), during the present manufacturing process no loss of 
viability was observed during spheronization even though a high rotation speed was used 
(1875 rpm). This can be attributed to protection of live cells by the excipients chosen, 
specifically the calcium crosslinked alginate that it is believed to have maintained the 
integrity of the matrix, and/or the presence of lyoprotectants such as polysaccharides in the 
formulation such as lactose that could protect bacterial cells by stabilizing the osmotic 
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pressure and replacing water during drying (Bajaj et al., 2010; Ohtake and Wang, 2011). 
Indeed, this study confirmed that drying is the most challenging process step for LBC and 
the use of drying protectants and mild processes was critical to maintain cell viability. The 
final step was spray coating with an enteric polymer, which can lead to further thermal 
stresses if enteric coating process requires heating for example in a fluid bed during spray 
coating; we therefore developed coating conditions that did not impact upon cell viability. 
Process conditions were selected that minimised the rate of moisture penetration into the 
spheres, thereby reducing the likelihood of rehydrating cells followed by drying them again, 
which would be expected to reduce viability. The fluid bed drying temperature was also kept 
low (35 °C) to avoid thermal stresses. The application of an enteric coating to achieve 
gastric acid protection also resulted in a significant enhancement of the surface morphology, 
from discontinuous and irregular to continuous and smooth. In addition, by increasing the 
sphere diameter and strength it was possible to improve the resistance to crushing, whilst at 
the same time the release rate was not significantly reduced. Worth noting that although this 
process maintained high levels of L. casei cell viability, previous studies have identified high 
variation in cell survival during extrusion-spheronization between different strains (Brachkova 
et al., 2009), with Gram positive strains typically showing better survival than Gram negative 
(Kouimtzi et al., 1997). Therefore, further process optimisation will be likely required to 
formulate different therapeutic live bacteria to the model one used in this study.  
 
Protecting dried cells from gastric acid 
To be effective, probiotic bacteria need to be delivered alive in the distant small 
intestine or colon. L. casei is sensitive to acid (Figure 7), confirming that this strain is unlikely 
to survive passage through the stomach if not administered within a protective formulation. 
The addition of polysaccharides to the matrix can provide acid protection (Cook et al., 2011), 
which is consistent with the partial acid protection seen with the uncoated DLPS. Maximal 
protection from acid was only obtained for the coated DLPS, and for this formulation no 
significant fall in viable cell numbers was observed in 6 independent experimental repeats 
(Figures 7&8). This protection was most likely achieved by the combination of two layers of 
acid protection; firstly the enteric polymer with a pKa of 5.5 which was used to coat the core 
incorporating the cells diminished the rate of diffusion of fluid in and out of the spheres 
(Siepmann et al., 2008). Secondly, the sphere core has calcium alginate in the matrix which 
further improved gastric acid protection because it forms an acid gel in low pHs (Cook et al., 
2011). However, given the minimal swelling and lack of disintegration in acid of coated 
spheres, it is most likely that the enteric coating provided the majority of the protection seen, 
and the additional protection by the calcium-alginate containing core was not essential. 
However, spheres without alginate and lactose lacked the required release characteristics 
and so MCC alone spheres were not enteric coated and we did not measure directly the 
protection provided by the enteric coating alone. Furthermore, these highly dense non-
floating spheres will be most likely deposited at the bottom of the stomach, where due to 
their small particle size rapid gastric emptying is likely, minimizing the time in the harsh 
acidic environment and thus increasing cell survival (Rouge et al., 1998; Streubel et al., 
2006). 
The enteric coating thickness and the choice of polymer or polymer blends must be 
tailored to the active ingredient and target site. In a previous study, pellets were coated with 
several enteric polymers and various thicknesses applied to deliver layered L. lactis in the 
human ileum to help Chron’s disease treatment. At pH 6.0 increasing Eudragit L30D-55 
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thickness from 20 to 30 %, measured as mass gain, reduced the release rate of thymidine; 
conversely, at pH above 6.5, the increase of coating thickness did not affect release rate 
(Huyghebaert et al., 2005b). Hung and co-workers showed that a coating level above 10 % 
was necessary to completely cover the uneven surface of the pellets after extrusion-
spheronization (Hung et al., 2014). In another study using LBC loaded into pellets a coating 
thickness of at least 15 % was necessary for complete protection from acid (Brachkova et 
al., 2009). Based on these observations and surface morphology of the uncoated spheres a 
coating level of 20 % was selected to ensure total acid protection and to improve sphere 
morphology. Furthermore, as it was clear that the time taken before onset of granule 
disintegration was increased by the enteric coating, the coating thickness was chosen to 
ensure that the time required for sphere disintegration, was suitable to control delivery into 
the distal small intestine. Depending on the release site desired (i.e. distal small intestine or 
colon) further alteration of the enteric polymer coating thickness is possible, either to delay 
disintegration for colon targeting, or to allow more rapid disintegration to target the proximal 
small intestine. 
Although the simulated gastric fluid used in this study was chosen as a mean gastric 
pH from fasting adults, the pH encountered after oral delivery can range considerably. 
However, the enteric polymer used, Eudragit L100-55, is a well characterised copolymer of 
methacrylic acid and ethyl acrylate (1:1 ratio) with a pKa of 5.5, is designed to prevent acid 
penetration as long as the pH remains significantly below this pKa, and so we expect similar 
protection from acid across the full range of gastric pH found in vivo. Furthermore gastric 
fluid contains additional components such as enzymes and surfactants that can have a 
significant impact on dissolution, penetration and disintegration of any given formulation. For 
these reasons, ultimately in vivo studies are required to fully establish the efficacy of live cell 
delivery from this formulation.  
 
Release of live cells under intestinal conditions 
There are two mechanisms of release from dried solid spheres: dissolution and/or 
disintegration leading to the dispersion of the matrix, or alternatively diffusion out of the 
matrix. For the LBC delivery matrix disintegration or complete dissolution is essential, as the 
micrometer size of L. casei cells dramatically limits diffusion rates, and live cells are unable 
to pass through most types of porous matrix and certainly the alginate gel used in this study, 
which typically has a pore size less than 200 nm (Gombotz and Wee, 1998). Disintegration 
was monitored visually, but swelling data and surface morphology also provided an insight 
into the mechanisms of disintegration. 
The disintegration of spheres formed from MCC alone vs alginate/MCC/lactose 
combinations either uncoated or coated were compared to identify formulations suitable to 
deliver large biotherapeutic agents. Spheres formed from MCC alone failed to disintegrate 
(Figure 4), which ruled out this simple formulation as unlikely to release LBC, and agrees 
with previous studies demonstrating that higher MCC content prolongs the disintegration 
time, giving sustained drug release (Kilor et al., 2010; Kranz et al., 2009). Soluble sugars 
such as lactose, and biopolymers such as alginate are biocompatible, good pelletization 
agents and can promote disintegration (Dukić-Ott et al., 2009). A previous study evaluated a 
range of MCC quantities and established that optimal Lactobacillus survival was found with 
between 40 – 60 % MCC (Bajaj et al., 2010), and we found 50 % MCC suitable. Crucially, 
although the enteric coating delayed disintegration from around 20 minutes to around 60 
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minutes (Figure 5c), even when coated, the alginate/MCC/lactose blend still gave rapid and 
complete disintegration once the coating had fully dissolved in SIF. 
In simulated GI solutions the degree of swelling can indicate firstly the structural 
integrity of the spheres and their ability to protect from acid (low swelling desirable) and 
secondly release at neutral pH (fast and high swelling desirable). At gastric pH (pH 1.8) 
swelling was minimal and slow and spheres did not disintegrate, confirming the integrity of 
the enteric coating (Figure 5). The high swelling followed by disintegration in high pH 
indicates that the spheres will most likely rapidly disintegrate in the small intestine releasing 
the LBC, as required. Cook et al studied the swelling behaviour of probiotic alginate-chitosan 
coated microcapsules in various gastric pHs and in intestinal pH, and at pH 2.0 the swelling 
profile was similar to the results here (Cook et al., 2011), but in contrast at intestinal pH the 
opposite was observed with coated spheres swelling more than uncoated. In contrast to the 
alginate-chitosan coating used in that study, DLPS used an acrylic polymer coating that was 
four times thicker, which may explain the slower swelling times and should provide improved 
acid resistance.  
SEM imaging identified cracks at the uncoated spheres surface which allow rapid 
solution penetration on immersion, which explains the faster swelling observed for uncoated 
spheres in high pH. However, after coating a smooth surface was formed which may 
contribute to the far lower swelling and slower release kinetics observed with coated vs 
uncoated (Fig. 2, 4 and 5). 
Finally, to evaluate whether the optimized DLPS formulation is suitable for intestinal 
delivery, cell survival and release was studied in vitro during simulated GI transit. Uncoated 
and coated DLPS were placed for 2h in SGF and transferred into SIF for 3h. Although visual 
inspection showed no sign of disintegration, some cells were released in SGF from the 
uncoated spheres, but not from coated DLPS. Given the poor survival of unformulated L. 
casei in SGF (Figure 7) this is likely to be an underestimate of the number of cells actually 
released, since many cells released were unlikely to remain viable for long. These released 
cells are probably from the surface of the solid sphere or from pores in the material, and are 
being released during swelling and erosion. These confirm the need and suitability of the 20 
% w/w enteric coating to achieve both total acid protection and distal intestinal release of live 
cells. Like gastric conditions, in vivo intestinal conditions vary significantly and many different 
agents are present that can not only affect sphere dissolution and disintegration, but some 
microbicidal agents are present that can further impact on bacterial cell viablity. For 
example, some dried probiotic strains and live bacterial vaccines show increased sensitivity 
to bile (Edwards and Slater, 2008; Mahbubani et al., 2014) For this reason, further study of 
cell viability in complex simulated gastrointestinal fluids and ultimately in vivo studies are 
essential to confirm the efficacy of this formulation for therapeutic live cell deliver. 
 
Conclusion 
The developed dried live probiotic sphere formulation represents an alternative to 
other oral formulations for LBC including tablets, capsules, pellets and microcapsules. 
Benefits of this new low-cost and scalable process include avoiding additional steps for 
lyophilisation of bacteria prior to formulation, use of conventional formulation equipment, 
increased number of live cells per dose, and reduced overall processing time. Coated DLPS 
effectively protected the L. casei cells from gastric acid and additionally delayed their release 
in SIF, suggesting that this formulation is ideal for efficient distal intestinal delivery of viable 
cells. The aim of this study was achieved, and a therapeutically relevant dose of 108 CFU of 
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probiotic strain was released within 1 h after transfer into SIF following 2 h exposure to SGF. 
Further studies are warranted to determine the storage stability of the formulation and viable 
cell delivery in conditions that fully simulate GI conditions using more complex gastric and 
intestinal fluids, for example including enzymes and bile. Ultimately the efficacy of this oral 
formulation for delivery of therapeutic live bacteria and live attenuated bacterial vaccines 
needs to be tested in preclinical or clinical studies. 
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Table 1. Appearance, shape (aspect ratio, circularity) and crushing strength of DLPS 
with or without coating. 
 
Figures 
 
Figure 1. Concept and experimental work – Production of Dried Live Bacterial 
Spheres (DLPS) by extrusion- spheronization. 
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Figure 2. Scanning electron micrographs of DLBS. The surface morphology (a, b, e, f) 
and interior (c, d, g, h) were examined by SEM. Uncoated spheres: a) uncoated sphere 
(bar=500µm); b) surface morphology of uncoated sphere (bar=100µm); c) interior of 
uncoated sphere (bar=400µm); d) cross-section of surface of an uncoated sphere 
(bar=100µm). Enteric coated spheres: e) enteric-coated sphere (bar=500µm); f) surface 
morphology of enteric-coated sphere (bar=100µm); g) interior of enteric-coated sphere 
(bar=400µm); h) cross section of a coated sphere showing coating and interior (bar=20µm). 
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Figure 3. FT-IR spectra of the enteric polymer (Eudragit), uncoated and coated 
spheres.  
 
Figure 4. Disintegration of (a) MCC; (b) uncoated and (c) coated DLPS in 
simulated gastrointestinal conditions. L. casei cells were encapsulated into MCC, 
uncoated and coated DLPS. These formulations were exposed to simulated gastric 
conditions by immersion in SGF for 2 hours, filtered and transferred into SIF for 24 hours. 
Images were taken at different time points to observe disintegration and degree of swelling. 
Similar results were observed in 3 different experiments. 
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Figure 5. Swelling behaviour of uncoated (triangle) and coated (diamond) DLPS 
in gastrointestinal solutions, (*) disintegration of the spheres. DLPS were placed either 
directly in SGF (pH 1.8, 2 h) and SIF (pH 7.0, until disintegration) or in SIF follow 2 hours in 
SGF. Images were taken at different times and swelling assessed. Results are 
representative of 4 repeats (mean ± standard deviation).  
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FIGURE 6. Cell viability during manufacturing process. L. casei cells were grown 
overnight, resuspended in CaCl2, mixed with the formulation components in an overhead 
stirrer for 15 min, extruded at 50 rpm through a 4 mm radius/ 1 mm diameter die, 
spheronized at 1875 rpm, dried at 40 ºC for 35 min in a fluid bed dryer and enteric coated 
until 20 % mass gain was achieved. Survival was tested by comparing the direct release of 
cells from each process step into simulated intestinal fluid (SIF) and cell counts adjusted to 
wet mass water content. *: p < 0.05. Viable cell recovery was significantly reduced by drying 
(p < 0.05). Data represent mean values 
and error bars indicate standard 
deviation (n=3). 
 
 
Figure 7. Survival of free and 
encapsulated L. casei cells in 
simulated gastric conditions. L casei 
cells were resuspended in simulated 
gastric fluid, pH 1.8 and incubated for 2 
h. At time 0 h and 2 h after challenge 
samples were taken and viability 
assessed. *: p < 0.05. Viable cell 
recovery was significantly reduced by 
acid conditions compared to time 0 h (p 
< 0.05). Results are representative of 3 
repeats (mean ± standard deviation).  
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FIGURE 8. Controlled delivery of probiotic live bacterial cells from DLPS in 
simulated gastrointestinal conditions. L. casei cells were prepared using the process 
described in Figure 7 and DLPS were made with no coating or with 20 % mass gain of 
enteric coating. To mimic gastrointestinal passage DLPS were immersed in SGF for 2 hours 
followed by transfer into SIF for 3 hours and viable cell recovery determined at indicated time 
points. Similar recovery and kinetics were observed in 3 different experiments. 
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